Podcasts about CSL

In this interview, Sarah sits down with Steven, a longtime UX leader who spent 17 years at the same digital agency before an unexpected layoff forced him to re-evaluate everything. With no portfolio, no updated resume, and low confidence, Steven joined Career Strategy Lab, and everything changed.Today, Steven is thriving as a fractional product design director, long-term contractor, and consultant helping companies elevate their UX teams and integrate AI into their workflows. In this conversation, he shares how Career Stratgegy Lab's UX job search accelerator helped him rebuild his confidence, tell a clear story about 20+ years of experience, streamline his job search, and even reinvent himself as a business owner.Whether you're mid-career, coming out of a layoff, or curious about consulting, Steven's story is a grounding reminder that clarity, strategy, and community can completely change your UX career trajectory.What You'll Learn in This Episode:✔️ How Steven went from 25% confidence to 80% confidence in his job search✔️ The myth he had to unlearn: your portfolio is not the first step✔️ Why clarity + foundational work = faster, less stressful job search✔️ How CSL's community accelerated his progress and kept him motivated✔️ The mindset shift that helped him stop applying blindly to jobs✔️ How he now uses CSL's frameworks to land consulting and contract roles✔️ Why your “career operating system” needs ongoing updates✔️ How knowing your values helps you choose the right opportunitiesTimestamps:00:00 Introduction to Sarah Doody and Career Strategy Lab00:38 Episode Overview and Open House Context01:26 Sarah Doody's Background and UX Career Coaching02:31 Steven's Journey and Career Strategy Lab Experience04:13 Building Confidence and Telling Your Story06:25 The Power of Community and Networking09:55 Mindset Shifts and Career Value Criteria13:03 Freelance and Consulting Success Tips16:01 Final Thoughts and Advice18:53 Conclusion and Next Steps

We love to hear from our listeners. Send us a message.On episode 117, Host Erin Harris welcomes Paul Perreault, Strategic Advisor, Board Member and former CEO of CSL, who shares insights from his decade leading the company through global expansion and the COVID-19 pandemic. Perreault highlights the importance of patient-centered culture, strategic focus, and adaptive leadership for cell and gene therapy innovators. He offers practical advice on building a values-driven culture that connects employees to patients, the importance of focusing on core competencies to attract capital, and the necessity of continuous leadership development, even advocating for mentorship and emotional intelligence as growth drivers in fast-evolving organizations.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

In this special coach takeover episode Erin, one of the coaches inside Career Strategy Lab's UX job search accelerator, breaks down the three most important things UX and product professionals should focus on in Q4 to set themselves up to get hired in Q1 of 2026.Whether you're feeling stuck, doubting your materials, overwhelmed by your portfolio, or unsure what support you actually need, this episode gives you a strategic and human approach to moving your job search forward.Erin shares what she and the CSL team are seeing every week while reviewing resumes, portfolios, and LinkedIn profiles—and the biggest patterns that determine whether someone gains traction or stays stuck in place.What You'll Learn in This Episode:✔️ Why you must rethink who you're getting job search feedback from✔️ How inaccurate feedback erodes confidence—and what to do instead✔️ The “back to basics” portfolio reset that outperforms flashy trends✔️ Why hiring managers want clarity over cleverness (and no, you don't need animations)✔️ How to build trust through your case study storytelling✔️ How to determine what level of support you actually need—structure, community, coaching, or therapy✔️ Why Q4 is the perfect time to prepare for Q1 hiring surgesTimestamps:00:00 Introduction to Career Strategy Lab00:38 Three Key Strategies for Getting Hired in Q1 202601:11 Assessing Feedback on Your Career Materials05:50 Back to Basics: Improving Your Portfolio09:19 Getting the Support You Need16:04 Recap and Final Thoughts18:49 Conclusion and Additional Resources19:32 Special Message for Job Seekers

The ASX 200 dropped 49 points to 8565 (0.6%) after a promising start. US futures in the negative hurt sentiment, together with Japanese losses on higher rates coming. Losses pretty much across the board, CSL fell 1.4% on vaccine concerns, the banks wilted with the Big Bank Basket down to $262.95 (0.7%). ANZ falling 1.3% and financials under pressure, HUB down 4.5% and NWL falling 4.0%. MQG dipped 0.4%. REITS slid with SGP down 2.3% and VCX off 1.2%. Industrials also sliding, TLS down 1.2% with CPU falling 3.3% and REA off 0.8%. Tech slipped, WTC down 2.6% and TNE falling 2.1%. Retail also in the doldrums, TPW resumed the dive, off 7.3%, APE similarly off 2.1% and NCK down 3.0%.In resources, Iron ore majors held firm, gold miners were mixed despite bullion rising, EVN down 1.9% and lithium stocks depressed, PLS off 3.2% and MIN down 3.9%. Oil and gas stocks rose, WDS up 0.9% and uranium stocks mixed.In corporate news, AUB smashed 17.8% lower as the bid was withdrawn, TWE has cleared the decks for the new CEO with a $687m impairment on US goodwill. PME dipped 1.6% on another order, the ASX itself had issues this morning with its announcement platform falling 2.8% as many stocks were put into a trading halt.Nothing on the local economic front. Japan opened the door a little further on rate rises.Asia markets mixed, Japan down 1.8%, China up 0.8% And HK up 0.8%.10-year yields pushing to 4.56%.US futures – Dow down 267 Nasdaq down 273. The holiday season is over.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Black Friday panic, Christmas chaos… and a derivatives-led global equity sell-off. In this episode of Talk Money To Me, Candice and Felicity zoom out from the noise and share six major investment themes set to shape portfolios in 2026 plus the ETFs, sectors and stocks they're watching right now.Recorded on 25 November 2025 following a sharp but non-fundamental global equity pullback driven by CTAs, futures activity and a VIX spike, the pair break down why retail investors have been buying the dip, not selling it and why the medium-term setup for equities remains constructive.They then reveal their 2026 Playbook, covering:⭐ Theme 1 – Mid-Duration Fixed Income & Floating RatesWhy the 3–5 year part of the curve, senior bank notes, floating-rate notes and diversified bond ETFs (like MQSD) are compelling defensive anchors heading into an uncertain rate environment.

Today's episode deals with a question from listener Michael, via LinkedIn: What in the world has happened with CSL? Downgrading guidelines, some board member transitions, vaccine business segment demerger, and a huge drop in stock price!Steve Wheen, Head of Healthcare, and Managing Director of Equity Research at Jarden, talks to Sean Aylmer about CSL and the rest of the healthcare sector.This is general information only. Seek professional advice before making investment decisions.Find out more: https://fearandgreed.com.au/See omnystudio.com/listener for privacy information.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramTransitioning from academia to UX can be daunting, but Ellen's story proves it's possible. After 17 years as a professor, Ellen pivoted to a Senior Content Designer role at TD Bank, with Career Strategy Lab providing the strategy, clarity, and confidence she needed to make the leap.In this episode, Ellen shares how CSL helped her reframe her experience, confidently communicate her transferable skills, and land her UX role—all while navigating the challenges of switching careers.What You'll Learn in This Episode:✔️ How Ellen navigated the shift from academia to UX✔️ Why confidence was her biggest challenge and how CSL helped her overcome it✔️ The importance of understanding how to communicate transferable skills✔️ How she used the Compass Statement to connect her past experience to her new career✔️ The value of having a portfolio and LinkedIn that clearly reflect your skills✔️ Ellen's tips on standing out during the job search with an authentic, tailored approachTimestamps:00:00 Introduction to Sarah Doody and Career Strategy Lab00:38 Episode Overview and Open House Context01:25 Sarah Doody's UX Career Coaching Journey02:29 Alan's Career Transition Story03:39 Building Confidence and Skills with CSL08:33 Mindset Shifts and Life Lessons10:47 Practical Tips for Job Seekers12:40 Final Thoughts and Encouragement14:04 Podcast Outro and Additional Resources14:44 Special Message for Job Seekers ⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

A solid start to the week with the ASX 200 up 109 points to 8525 (1.3%). Across the board gains, with US futures pointing slightly higher too. Banks were better led by CBA up 1.2% and the Big Bank Basket up to $268.55 (1.1%). Financials were generally firm, even GQG up 0.6% and SOL rising 1.8% as it joined with Genesis to make a bid for MVF at 80c. Insurers rose, QBE up 1.4% and REITs did well, GMG up 2.1% and SGP rallying 2.3%. Industrials in the green, WES up 0.2% and ALL rising 0.5% with TCL up 2.0% and RMD up 2.2% better in healthcare. CSL too had a good day. PME rose 3.5% on new orders in America.  TLS rose1.9 % and REA up 1.9%. Resources were mostly better, BHP up 0.6% with its on/off bid for Anglo, RIO rose 1.1% and FMG up 1.9%. Lithium stocks gave back some recent gains, MIN down 3.2% and PLS down 3.6% with gold miners up, GMD up 1.3% and rare earths also doing better. Oil and gas stocks slid on crude falls, WDS down 1.3% and uranium stocks slightly better.In corporate news, QUB were approached by Macquarie with a 520c NBIO whilst MVF rose 44.3% on a 80c bid. MYX returned to trade after the Treasurer knocked back the Cossette bid. DRO rose 1.8% after some more news on the recent share sales and a new US MD. IRE soared 8.0% before a trading halt concerning continuous disclosure.Asian markets weaker with Japan closed for a holiday, China down 0.6% and HK up 1.4%.European markets set to open higher again.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the industry, exploring significant scientific advancements, regulatory changes, clinical trial outcomes, and strategic investments that are shaping the future of healthcare.Starting with strategic investments, Regeneron is making a bold move with a $2 billion investment to transform a former magazine factory in Saratoga Springs, New York, into a state-of-the-art drug manufacturing plant. This investment reflects a broader industry trend towards enhancing domestic manufacturing capabilities to ensure supply chain resilience. Similarly, CSL is channeling $1.5 billion into U.S. plasma-based manufacturing over the next five years. These investments are critical as plasma-derived therapies continue to play a vital role in treating various conditions, necessitating robust manufacturing infrastructure to meet growing demand.In clinical research, Merck's Winrevair has shown promising results in a proof-of-concept study for heart failure patients. This advancement highlights ongoing efforts to address one of the leading causes of morbidity and mortality worldwide—heart failure. The study paves the way for further exploration of activin signaling inhibitors in cardiovascular therapies.On the regulatory front, Eli Lilly has expanded its market reach with the approval of its Alzheimer's medication for distribution in India. This milestone represents progress in tackling the global Alzheimer's disease burden, an ailment that presents significant challenges to healthcare systems worldwide.The FDA's recent critique of AstraZeneca's Farxiga advertisement underscores the importance of accuracy in pharmaceutical marketing. The agency's concerns about potential misleading impressions emphasize ongoing regulatory vigilance to align marketing practices with approved therapeutic uses and ensure patient safety.Shifting to business strategies, Zymeworks' transition towards becoming a 'royalty-driven organization' marks an evolution in biotech business models. By leveraging successful licensing frameworks, Zymeworks aims to enhance revenue streams while focusing on innovation without the traditional constraints of direct commercialization.In cardiovascular therapeutics, Cytokinetics is positioning itself strategically by funding a heart registry, signaling an intensifying competitive landscape as companies vie for leadership in this critical area of healthcare.Roche's development of giredestrant, an oral selective estrogen receptor degrader (SERD), has achieved success in a phase 3 adjuvant breast cancer trial. This positions Roche to capture an unoccupied niche within the competitive breast cancer treatment market and highlights a trend towards targeted therapies with potentially significant patient outcomes.Addressing side effects associated with GLP-1 receptor agonists, Vanda Pharmaceuticals is making strides with tradipitant to mitigate nausea and vomiting induced by Wegovy. As GLP-1 agonists gain traction for their metabolic benefits, adjunct therapies addressing side effects are becoming increasingly pertinent.In digital health initiatives, Humana's collaboration with Epic aims to automate insurance verification and patient check-ins, aligning with federal interoperability goals. This represents a broader industry shift towards digital solutions designed to streamline administrative processes and enhance patient experience.Meanwhile, Lonza's expansion at its Stein facility in Switzerland underscores ongoing capacity-building efforts among contract development and manufacturing organizations (CDMOs). Such expansions are crucial as they provide biopharmaceutical companies with the neSupport the show

Wall Street extended its losing streak, with the S&P 500 falling for a fourth straight day as investors braced for Nvidia’s high-stakes AI results. In company news, Microsoft and Nvidia announced plans to invest up to $15 billion in Anthropic, while Home Depot slipped after cutting its forecast on weaker demand. In the commodities market, oil prices steadied as traders weighed the impact of Russian sanctions. Back home, Aussie shares are expected to hover near five-month lows on Wednesday ahead of wages data, while CSL plans to invest $1.5 billion in US drug manufacturing. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The ASX 200 closed up 2 points to 8636 in a quiet session ahead of a big week in the US. Good comeback after a near 50 point fall this morning.  Some signs of confidence returning with banks seeing a resumption of the sell CBA, buy the other three switch. The Big Bank Basket fell to $272.47 (-0.4%) as CBA dropped 1.0%. MQG ex-dividend today, down 2.3% with financials slightly firmer, QBE up 0.5% and HUB up 2.7% with NWL gaining. REITs firmed, GMG up 0.5% and CHC up 1.7% with industrials finding their feet, LNW up 3.3% with WTC up 1.2% although XRO fell another 0.1%. Retailers firmed, UNI up 1.7% and PMV up 2.1% with DMP gaining another 5.1%. GYG continue to fall, down 1.8%. Healthcare eased back, RMD under pressure off 2.1%, CSL down 0.8% and SHL slipping 1.5%. Resources were mixed, BHP fell 0.6% on the UK court ruling, RIO and FMG both better on higher iron ore prices in Asia, lithium staged a comeback, PLS up 3.7% and IGO rising 0.9%. LYC also bounced 5.5% with gold miners mixed. No significant damage done. GMD up 2.5% on a broker upgrade. Energy stocks all better, WDS up 0.9% and ALD rising 3.8%. IPX fell 3.0% after a return to trade following a report from Spruce Capital.PME jumped 4.2% on another $44m deal with Advanced Radiology. Some management changes, RHC rose 1.8% on a new CFO, MSB rallied 5.0% on a new CFO too with FPR better on an acquisition. ELD gained 6.3% on better than expected results.Nothing locally on the economic front. RBA board member wrote a column on the RBA mandate. In Japan, GDP came in better than expected.Asian markets weaker with Japan down 0.4%, China down 0.4% and HK off 0.6%.European markets set to open slightly weaker.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

In this episode, Sarah sits down with Phoenix, a Career Strategy Lab (CSL) member who shares what it's like to be in the middle of their UX job search transformation.Phoenix opens up about the identity crisis that came from trying to be what companies wanted and how shifting toward a product-thinking approach—treating their career like a system—led to clarity, confidence, and traction. This is a must-listen for any UX or product professional feeling stuck, unfocused, or uncertain about how to move forward in today's job market.You'll hear Phoenix share the exact moment things started to click, the biggest mindset shifts since joining CSL, and how things like a simple resume rewrite not only clarified their value—but also unlocked a potential $20K salary bump.Whether you're pivoting into UX, climbing toward leadership, or simply tired of second-guessing yourself, Phoenix's story will help you see what's possible when you stop trying to be someone you're not and start owning what you bring to the table.What You'll Learn in This Episode:✔️ How Phoenix went from feeling irrelevant to in control of their UX career✔️ Why “conforming” to what employers want actually backfires—and what to do instead✔️ The power of the compass statement and how it transforms resumes, portfolios, and interviews✔️ How systems thinking applies to both UX and job search strategy✔️ The emotional journey of building a personal brand that reflects your true strengths✔️ Why clarity is more powerful than pep talks when it comes to confidenceTimestamps:00:00 Introduction to Career Strategy Lab00:38 Episode Overview and Open House Context01:22 Q&A with Phoenix: UX Job Search Insights03:59 Phoenix's Journey: From Uncertainty to Clarity07:33 The Power of a Strong Resume and Compass Statement20:04 Emotional Impact and Personal Growth24:19 Advice for Job Seekers and Final Thoughts

The ASX 200 kicked 66 points higher to 8836 (0.8%) as news of a Senate vote to end the shutdown brought risk appetite back. ANZ results helped the banking sector as the market warmed to the transformation story, with the stock hitting record highs, up 3.2%. The Big Bank Basket rose to $295.69 (0.2%) with CBA slipping slightly.Financials were better, as MQG found some analyst love and ZIP rose 4.5% on Nasdaq listing news. NWL rallied 2.4%, with XYZ bouncing hard, up 6.9%. Insurers firmed; REITs were mixed, with GMG down 1.3% and SCG up 0.7%.Healthcare was also mixed as CSL fell 0.1% and RMD rose 0.6%. Industrials perked up after a lacklustre start, TLS up 0.6% with QAN rallying 2.3%, and the tech space doing well — WTC gained6.2 % and XRO rose 1.0%, with the All-Tech Index up %.Resources were also in demand — gold miners kicked higher, NST up 3.5% and EVN up 3.9%. Lithium stocks enjoyed a day out, PLS up 9.2% and MIN gaining 4.0%. Rare earth stocks were back in favour, LYC up 4.8% and ARU rallying 7.8% to its SPP price. Energy stocks were also in demand, WDS up 1.2% and PDN rose 7.9%, with LOT up 5.9% as uranium found favour.In corporate news, MND rose 11.0% on a trading update, DOW hit a five-year high on a solid opening higher $750m Chevron deal, and DNL exploded 7.8% higher on improved results. AUB flat on news that CVC Asia joined the fray. AGL rose 1.6% after it agreed to divest its stake in Tilt Renewables. MYX fell 5.9% on news Cosette will appeal the court decision.Asian markets – HK up 0.9%, China off 0.1% and Japan up 1.3%.  US futures strong on shutdown hopes. Nasdaq up 307 Dow up 98. European markets set for a strong opening. Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Health editor Michael Smith discusses CSL’s remarkable story, why investors have lost faith in the healthcare giant and what Trump has to do with it. This podcast is sponsored by Aussie Broadband Further reading: How CSL went from 'bloated bureaucracy' to $145b global behemothWhen Brian McNamee took on the top job at Commonwealth Serum Laboratories, the government-run entity was barely worth the land it was built on.McNamee vows to stay CSL chairman despite growing investor disquietThe pharmaceutical giant has avoided a board spill, but a market bloodbath arising from declining US vaccine rates has investors seething.‘We have to fix this’: Brian McNamee on turning around CSLCSL was once a market darling, now it’s out of favour and pressure is on board and management to convince sceptical investors of a plan to restructure the business.See omnystudio.com/listener for privacy information.

The ASX fell another 12 points to 8802, well off lows, as resources were slammed hard. The market finished well off the lows of the day as US futures recovered from heavy early losses. Banks held up again, CBA up 1.3% and the Big Bank Basket up to $297.93 (+0.9 % ). MQG dropped 0.4%, and financials were mixed — ASX up 1.6% and GQG off 1.7% again. Insurers saw small gains, SUN up 0.6% and MPL up 1.2% on an acquisition. Industrials were mixed, TLS rose 1.5% with BXB recovering slightly, WOW and COL rose, and TCL up 0.8%. Tech stocks fell, XRO off 0.9% and WTC continuing to fall off 1.4%. The All-Tech Index was down 1.7%. Healthcare stocks were mixed — CSL fell 0.4% despite a briefing on vaccines this morning, RMD up 0.6%, and PME slipping 1.4%.Resources tumbled, BHP off 0.5% with FMG down 2.5%, though well off the lows. Gold miners saw small losses even as bullion pushed higher. Lithium stocks fell hard, PLS down 3.3% and MIN off 3.4%. Rare earths saw heavy losses, LYC off 3.3% and ILU down 3.6%. Second-liners like ARU fell 5.7%, well below the SPP placement price of 28c.In corporate news, TYR appointed Nigel Lee as new CEO, GMG fell 3.4% on an AGM update. WDS looking to boost cashflow.Nothing on the economic front here. Asian markets crumbled in places — the Nikkei 225 dropped the most since April, as tech valuations came under scrutiny.Asian markets - HK up 0.1% China up 0.1% and Japan down 1.5% 10-year yields 4.31%. US Futures off lows, Nasdaq down 52. Dow up 56.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX200 slid 0.9% (81 points) to a five‑week low after the RBA left rates at 3.6%. Hotter‑than‑forecast inflation curbed cut hopes. All sectors except healthcare fell, with Westpac the sole bank up 1.5%. City Chic rose 7.5% after a solid ANZ update, while CSL remains down 40% YTD. Focus now shifts to inflation data on 26 Nov and upcoming employment and earnings releases. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The ASX 200 started badly down some 40 points but rallied to close up 13 at 8892 (0.2%). Once again it was the banks that led the turnaround with WBC numbers pleasing and the sale of the RAMS Home Loan book also a positive. The bank closed up 2.8% with the Big Bank Basket at $297.33 (+2%). CBA kicked up 2.3% and other financials were mixed. REITs slid with GMG down 0.2% and SGP off 0.8% and insurers also fell, QBE down 1.2%. Industrials ended up mixed, after a sluggish start, WES up 0.3% and REA bouncing 1.1%. Tech stocks did better, WTC up 0.6% and XRO rallying 2.3%. In the healthcare space, RMD fell 4.3% on its results, CSL continued to drag the sector down, off another 1.7%.Resources were weaker on Chinese data, BHP down 0.2% and rare earths spluttered lower, LYC off 8.1% and lithium depressed, PLS down 5.2% and LTR off 0.4%. Gold miners eased back as bullion tested $4000, NST down 2.0% and EVN off 2.5%. Oil and gas stocks rose as crude pushed ahead, WDS up 1.3% and STO up 1.1%, uranium drifted lower, PDN down 2.0%.In corporate news, DRO steady on a Latin American order, DMP rose 0.2% after selling its printing business.Asian markets mixed, HK up 0.1%, China up 0.2% and Japan up 0.9%.10-year yields 4.35%. US futures slightly higher.Want to invest with Marcus Today? Our MT20 portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic landscape of scientific breakthroughs, regulatory shifts, and strategic maneuvers reshaping the industry.BioMarin's recent decision to divest from its hemophilia A gene therapy, Roctavian, has garnered significant attention. Despite being the sole approved gene therapy for hemophilia A, Roctavian has struggled with sales since its launch two years ago. This move underscores the complex challenges in commercializing gene therapies, highlighting that even groundbreaking treatments can face hurdles in market penetration. It reflects broader implications for the commercialization strategies of innovative therapies and emphasizes that market acceptance is as crucial as clinical efficacy.In manufacturing and regulatory affairs, Regeneron is navigating hurdles with its Eylea HD due to persistent manufacturing issues. The FDA's complete response letter points to ongoing problems at a Novo Nordisk plant. This situation illustrates the critical role of manufacturing standards in securing regulatory approvals and ensuring consistent product availability. Regeneron's efforts to seek alternative manufacturing solutions emphasize the importance of compliance and quality assurance in the pharmaceutical landscape.Roche is advancing its kidney disease portfolio with a Phase 3 trial success for Gazyva against idiopathic nephrotic syndrome. Building on previous approvals for lupus nephritis, this achievement underscores Roche's strategic focus on expanding indications for existing biologics. It highlights the value of lifecycle management strategies in maximizing therapeutic potentials and extending the reach of established drugs.A significant shift in pharmacy benefit management is underway as Cigna's Evernorth division moves away from PBM rebates through Express Scripts. This transition towards a rebate-free model may influence industry-wide practices, addressing growing scrutiny over rebate structures criticized for their lack of transparency and their impact on drug pricing.CSL's decision to delay the spinoff of its flu vaccine unit amid declining U.S. immunization rates illustrates market challenges in vaccine uptake. The anticipated drop, particularly among older populations, raises public health concerns and underscores the necessity for enhanced outreach and education to improve immunization coverage.On the investment front, AbbVie, Regeneron, and Sanofi have collectively invested $80 million in ZAG Bio's Series A funding round. This company is developing thymus-targeted medicines for autoimmune diseases, reflecting continued interest in novel therapeutic approaches addressing unmet medical needs within the biotech space.Catalent's rebranding initiative signifies a strategic effort to align corporate identity with mission-driven objectives, emphasizing "missions that matter" as it approaches an anniversary milestone with Novo Nordisk's acquisition. Such rebranding efforts are critical for differentiating service offerings and reinforcing corporate values within competitive markets.The competitive landscape within diabetes and obesity treatment markets is experiencing a potential paradigm shift following the results from Innovent and Eli Lilly's Phase 3 trial of mazdutide. This dual GLP-1/glucagon receptor agonist outperformed Novo Nordisk's semaglutide, offering improved outcomes in weight reduction and glycemic control. Mazdutide's dual mechanism could redefine treatment protocols, offering patients enhanced therapeutic benefits.MapLight Therapeutics has successfully raised $250 million through an IPO to advance its schizophrenia treatment candidate, Cobenfy. This funding supports further clinical development and potential commercialization efforts, reflecting investor confidence in innovative neurologSupport the show

The ASX200 slipped almost 1% to its worst daily drop since 3 Sept, spurred by September CPI showing headline 3.2% and core at 3%, topping the RBA’s target. Markets now see only a 5% chance of a rate cut at the Melbourne Cup meeting. Energy and gold miners led modest gains, while financials and CSL fell sharply. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

SBS Finance Editor Ricardo Gonçalves speaks with Australia's Special Envoy to Southeast Asia Nicholas Moore to find out how regional leaders feel about doing business with Australians as he attends the ASEAN summit; plus Michael Jenneke from UBS Management takes a look at the day's sharemarket action as CSL and Wisetech shares crash.

The ASX200 fell about 0.5% today, erasing Monday’s gains, but stays up 2% for October and just 1% below a record high. Financials rallied, with the big four banks hitting record levels, while CSL and WiseTech drove the decline, dropping 16% and 15% respectively. Look ahead to tomorrow’s CPI release and the RBA’s likely rate cut on Melbourne Cup Day. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Police & ASIC have raided Wisetech Global offices, while CSL finds a tough crowd at its AGM.See omnystudio.com/listener for privacy information.

Ep. 335 Eternal Light - Rev. Mary Mitchell From the Sunday Service at the Center for Spiritual Living in Redding on 10-26-25

Ep. 334 Inner Knowing - Rev. Melissa Harris From the Sunday Service at the Center for Spiritual Living in Redding on 10-19-25

After being laid off and earning a Master's degree in UX, Melp still wasn't landing UX job interviews. What changed? She stopped applying to everything and started thinking strategically.In this Q&A from a Career Strategy Lab Open House, Sarah Doody talks with Melp, a UX researcher turned product manager, about the ups and downs of her UX job search journey. Despite years of experience, a Masters degree in UX from the University of Michigan, and hundreds of UX job applications, Melp wasn't getting traction, until she joined Career Strategy Lab.You'll hear how she slowed down to get clear, challenged the narrative that she was “difficult to work with,” and started positioning herself as a strategic asset (not a liability). Her confidence began to rebuild, not because of a new certification, but because she finally saw her work for what it was: valuable.What You'll Learn in This Episode:✔️ Why Melp chose strategy over hustle in her UX job search✔️ How the Career Compass Sprint helped her identify what she really wanted✔️ The mindset shift from “I'm difficult” to “I'm a high-impact team member”✔️ Why she stopped over-preparing and started owning her story✔️ How CSL's “minimum viable portfolio” mindset freed her up to move forward faster✔️ The difference between traditional career support and CSL's strategic, in-depth processTimestamps:00:00 Introduction to Career Strategy Lab02:14 Melp's Career Journey and Challenges03:39 The Importance of Finding the Right Job05:25 Deep Dive into Career Compass Sprint07:02 Confidence and Self-Discovery09:02 The Diva Mindset and Environment Fit17:02 CSL's Unique Approach and In-Depth Process22:18 Final Thoughts and Advice for Job Seekers24:13 Conclusion and Podcast Outro24:53 Special Message for Job Seekers

Ep. 333 Reverence for the Earth - Rev. Dr. Andrea Asebedo From the Sunday Service at the Center for Spiritual Living in Redding on 10-12-25

Ep. 332 Inner Illumination - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 10-5-25

The Aussie share market finished the week strongly, up 0.5% on Friday and 2.3% across the week, marking its best weekly performance since early May. Tech stocks led gains with Live360 and Block, Inc. among the top performers, while energy lagged as oil prices slipped to four-month lows. Eagers Automotive surged nearly 18% after announcing a major Canadian acquisition, while DroneShield climbed 50% for the week. Dividend payouts from CSL, A2 Milk, Origin, Domino’s and others also put extra cash in investors’ pockets, while attention now turns to US earnings season, a New Zealand rate decision and uncertainty from the US government shutdown. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

The ASX200 rose 1.2% to a one-month high, edging closer to 9,000 points in a broad rally led by gold, banks and healthcare. Gold miners surged as prices hit fresh records near US$3,900 an ounce, while CSL bounced almost 4% and the big four banks all advanced. Globally, investors weighed the US government shutdown, weaker jobs data and strong US pharma gains, while dividend season picked up with payouts from Breville, Seek and Treasury Wines. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Eis Sujete vun haut: Biller vum Trounwiessel ginn ëm d'Welt, CSL fuerdert Recht op Weiderbildung fir all Mataarbechter an zousätzlech Struktur vun HRS-Grupp

Pharma stocks plunge as Trump’s 100% tariffs send shockwaves across Asia. Hosted by Michelle Martin, we break down the impact on Singapore’s $4 billion pharma exports, Sumitomo Pharma, CSL, and more. Are these tariffs a short-term blow or a long-term reset for Asian healthcare investments? Plus, we spotlight Mapletree’s three Singapore REITs - Logistics, Industrial, and Pan-Asia Commercial - amid expected rate cuts. Which one offers the best dividend yield and growth potential? Dividend Titan’s Willie Keng shares his strategy for navigating healthcare risks and REIT opportunities. See omnystudio.com/listener for privacy information.

Ep. 331 Hope and Resilience - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-28-25

Tensions are high after NATO Secretary-General Mark Rutte warned Russia that its warplanes could be shot down if they stray over European territory, a stance backed by Donald Trump. Meanwhile, Trump has imposed a 100 per cent tariff on foreign-made pharmaceutical products.See omnystudio.com/listener for privacy information.

The ASX200 closed modestly higher on Friday, up about 0.08% and breaking a three‑week losing streak, while September remains down roughly 2%. Stronger‑than‑expected August inflation trimmed market expectations for a November RBA rate cut to about 50%. US President Trump’s 100% tariff on pharma imports dragged healthcare stocks such as CSL, Pro Medicus and Mesoblast lower, whereas miners (+0.7%) and financials (+0.5%) buoyed the index, led by BHP’s 1.3% gain. Looking ahead, investors will watch the RBA’s October decision, US inflation figures and upcoming US jobs data, plus the rollout of pharma tariffs on October 1. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Ep. 330 Listening to Spirit - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-21-25

Australian shares extended losses on Thursday, with the ASX200 down 0.8%. Energy stocks were the hardest hit after Santos tumbled nearly 12% on news a $30 billion takeover bid collapsed. CSL slipped below $200 for the first time since 2019, while Origin Energy and CBA also weighed on the market. In contrast, Nuix surged on a major contract win and uranium miners bounced back. Meanwhile, a weaker-than-expected jobs report adds weight to the case for an RBA cut later this year. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramAfter 18 months of job searching with no results, Mariah was out of steam and questioning everything—until she joined Career Strategy Lab.In this Open House conversation, Sarah talks with Mariah, a UX researcher and experience strategist with a background in customer support and consulting. Mariah came to CSL after burning out from a year and a half of job searching while trying to relocate to Copenhagen. In this honest episode, she shares what finally helped her stop spinning, reconnect with herself, and gain the clarity, confidence, and support she'd been missing.Whether you're new to UX or deep in burnout, Mariah's story will remind you that it's not too late—and you don't have to figure it out alone.What You'll Learn in This Episode:✔️ What job searching for 18+ months taught Mariah about burnout and boundaries✔️ Why trying to “game the system” kept her stuck and exhausted✔️ How the Compass Sprint reconnected her to her voice, identity, and strengths✔️ Why the mindset calls inside CSL helped her finally feel like herself again✔️ How to balance personal and professional identity in your job search✔️ Her advice for perfectionists and overthinkers: take action, even when it's messyTimestamps:02:27 Mariah's Background and Career Journey04:21 Joining Career Strategy Lab: Initial Experiences08:09 Impact of Mindset Calls11:50 Tangible Actions and Career Roadmap18:43 Final Advice and Closing Remarks21:22 Podcast Outro and Additional Resources22:03 Special Message for Job Seekers⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

Ep. 329 What is Calling You? - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 9-14-25

With Pfizer discontinuing Beqvez and BioMarin scaling back the commercial focus of Roctavian, the curative promise of hemophilia gene therapies is tempered by significant barriers that discourage widespread adoption. In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker speaks with Glenn Pierce, M.D., Ph.D., vice president of medical at the World Federation of Hemophilia, about the complexities behind these innovative therapies and the multifaceted reasons for their slow uptake. Pierce discusses the competitiveness of the current hemophilia gene therapy market, why Pfizer’s product couldn’t keep up, and the patient populations that risk being left behind. To learn more about the topics in this episode: As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio BioMarin downsizes Roctavian efforts but keeps hemophilia gene therapy for 3 markets See omnystudio.com/listener for privacy information.

CSL 裁员3000人，而公司利润明明在上涨。 这是否由AI 引发？普通人如何保住饭碗？Morgans 亚洲业务主管深度解析，点击收听，并欢迎您在SBS中文社交媒体平台留言，表达您的观点。

Ep. 328 You are Worthy…Simply Because - Rev. Dr. Mary Michell From the Sunday Service at the Center for Spiritual Living in Redding on 9-7-25

What do seminary school, a dairy burn room, and running a global biotech powerhouse have in common? Paul Perreault. In this episode of The Authority Company Podcast, host Joe Pardavila sits down with Paul Perreault, former CEO of CSL and author of The Detour CEO, to explore how a non-linear path shaped his values-driven approach to leadership. Paul opens up about working 80-hour weeks in a restaurant, scrubbing burnt milk, and studying to become a priest—all before leading a multi-billion dollar company. He shares why being a generalist is underrated, how to separate identity from work, and what it really means to “add value” in life and business. Whether you're navigating your own professional pivot or leading a team, Paul's insights on humility, culture, and the myth of the corporate ladder are worth the listen.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramWondering how to stand out in UX without burning out? Former technical recruiter Ellie shares her story of switching into product design—and how Career Strategy Lab helped her get her confidence back.In this episode, Sarah interviews Ellie, a former technical recruiter turned UX designer, who joined Career Strategy Lab while navigating new motherhood, burnout, and the unpredictable job market. Despite landing interviews, Ellie felt stuck—and knew she needed a structured, supportive way to rebuild confidence and stand out.You'll hear how she overcame perfectionism, reframed her job search, and built career habits that now extend beyond her portfolio and into her life.What You'll Learn in This Episode:✔️ Why Ellie left tech recruiting to pursue UX—and doesn't regret it✔️ What made her say “yes” to CSL (and why she wishes she joined sooner)✔️ How the Compass Statement gave her clarity and saved her time✔️ The unexpected life shifts that came from doing the work with intention✔️ Tips for breaking perfectionism and building habits that stick✔️ What it's like to join CSL while navigating new parenthood and burnoutTimestamps:00:00 Introduction to Career Strategy Lab00:38 Episode Overview and Open House Context02:23 Meet Ellie: From Technical Recruiter to Product Designer05:19 Ellie's Career Journey and CSL Experience09:16 The Impact of Career Strategy Lab18:47 Advice and Final Thoughts21:32 Conclusion and Next Steps⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

The guys destroy CSL and Reece’s WFH Excuse, Adir breaks down Site Minder’s huge surge, Qantas delivers a record result, Nvidia hits new highs but are grey skies looming, Blackbird’s Class of 2015, Sydney Outshines Dan Andrews’ Hellhole and KPop Rules. Thanks for listening! Join us on LinkedIn: https://www.linkedin.com/company/the-contrarians-with-adam-and-adir-podcast Subscribe on YouTube for all our video content: https://https://www.youtube.com/@ContrariansPodcast Follow us on Instagram: https://www.instagram.com/contrarianspod Follow us on TikTok: https://www.tiktok.com/@contrarianspodSee omnystudio.com/listener for privacy information.

Ep. 327 Love's Ascent - Rev. Sue MillerBorn From the Sunday Service at the Center for Spiritual Living in Redding on 8-31-25

Two years ago Mark purchased CSL. The share has not done well in that period. Mark goes through his thoughts on CSL, whether it still meets his original thesis, and evaluates whether the share deserves a place in his portfolio.You can find the full article here. A message from Mark and ShaniFor the past five years, we've released a weekly podcast to arm you with the tools to invest successfully. We've always strived to provide independent, thoughtful analysis, backed by the work of hundreds of researchers and professionals at Morningstar.We've shared our journeys with you, and you've shared back. We've listened to what you're after and created a companion for your investing journey. Invest Your Way is a book that focuses on the investor, instead of the investments. It is a guide to successful investing, with actionable insights and practical applications.The book is currently in presale which is an important time to build momentum. If anyone would like to support this project you can buy the book now. Thanks in advance!Purchase from Amazon or Purchase from BooktopiaTo submit any questions or feedback, please email mark.lamonica1@morningstar.com or leave us a voicemail to feature on the podcast here.Audio Producer and mixer: William Ton. Hosted on Acast. See acast.com/privacy for more information.

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 22, 2025. In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking's obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T77LV22VANAL5GNPCC2YUVLZBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

– RBA’s $1.2b renovation – Economic roundtable disappointment – CSL, James Hardie and Audinate hit for six – Qantas’ $90m fine and NAB’s $130m make-good – CBA’s AI SNAFUSee omnystudio.com/listener for privacy information.

Applied to 50+ UX or Product jobs & still no interviews or offers? Get UX job search help.Welcome to the Career Strategy Podcast with Sarah Doody, a UX Designer & UX Researcher with 20 years of experience who founded the UX job search accelerator, Career Strategy Lab. She's been doing UX career coaching since 2017.Follow Sarah on: LinkedIn | YouTube | InstagramLaid off and wondering if you've “missed your shot”? This story will change how you think about career momentum.In this Open House conversation, Sarah sits down with Manny, a senior UX designer who transitioned into UX after a decade in graphic design and just landed a role at Fidelity. After getting laid off and spending weeks spinning his wheels, Manny joined Career Strategy Lab to bring clarity, structure, and confidence back to his job search.In this honest and insightful conversation, Manny shares what helped him rebuild momentum, how the Compass Sprint shaped everything from his resume to interviews, and why he wishes he'd joined sooner.What You'll Learn in This Episode:✔️ How Manny landed a UX role at Fidelity after being laid off✔️ The single most valuable CSL exercise (that he didn't expect)✔️ Why clarity leads to faster progress across your materials✔️ How the Compass Statement helped him shape his story and stand out✔️ Why applying early in your job search saves you time, money, and confidence✔️ How to make the most of CSL—whether you're employed or notTimestamps:02:28 Meet Manny: A UX Designer's Journey03:51 Navigating Job Search Challenges06:16 The Impact of Career Strategy Lab12:27 Advice for UX Job Seekers14:54 Conclusion and Final Thoughts15:07 Podcast Outro and Additional Resources15:47 Special Message for Job Seekers⭐ Support the show! Leave a rating on Spotify or a review on Apple Podcasts to help more UX professionals find this podcast.

Qantas has copped a record $90 million fine for its illegal sackings of staff…and more than half of the money is going straight to the union. CSL, the Aussie biotech, is cutting almost 3000 staff globally, as part of the biggest shake-up of the last decade. Soho House, the members club, is going private again after battling in the public markets for the past 4 years. _ Learn more about iShares by BlackRock here Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay Daily newsletter: https://bit.ly/fluxnewsletter Flux on Instagram: http://bit.ly/fluxinsta Flux on TikTok: https://www.tiktok.com/@flux.finance —- The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes.__ Issued by BlackRock Investment Management (Australia) Limited ABN 13 006 165 975, AFSL 230 523. Refer to FSG available on our website. Before making any investment decisions, you should assess whether the product or service is appropriate for you and read the PDS and TMD available at blackrock.com.au.See omnystudio.com/listener for privacy information.